RFA-DA-25-062: HEAL Initiative: JCOIN Phase II Innovation Hubs (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $2.3 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 22, 2025.
From the official notice on Grants.gov, last changed June 6, 2024. Checked November 7, 2026.
- Award ceiling$2.3 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$707,660
- Typical project length4.5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-25-062 were run by National Institute on Drug Abuse (NIDA, 9 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-25-062 in the NIH Guide.
Key dates
| Posted | June 6, 2024 |
|---|---|
| Deadline | January 22, 2025 |
| Archived by Grants.gov | February 27, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $707,660; it allows up to $2.3 million per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if they have not received MOUD while detained. Most US jails do not offer MOUD to everyone who could benefit from them. JCOIN focuses on the translation of research-to-practice to address the overdose crisis in the context of the criminal justice system specifically, increasing delivery of and access to MOUD. A portfolio of research projects conducts hybrid effectiveness-implementation trials to address key barriers to delivery of evidence-based OUD treatments to justice-involved populations. This is the only HEAL initiative with a primary focus on justice-involved populations and criminal-legal systems.
Funded under RFA-DA-25-062 so far
NIH funded 9 projects under RFA-DA-25-062 in fiscal 2025 to 2026, at 7 institutions. The median yearly award was $707,660.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Optimizing Opioid Use Disorder Treatment in Prisons: Strategies for Diagnosis and Shared Decision-Making | University of Washington | 2026 | $673,676 |
| JCOIN phase II innovation hub | Emory University | 2026 | $576,899 |
| The impact of HB-139 on substance use outcomes: a natural experiment | New York University | 2026 | $703,384 |
| Improving Access to MOUD in Drug Courts through Inter-agency Collaboration: COLAAB Study | Univ of Massachusetts Med Sch Worcester | 2026 | $711,935 |
| Supporting Treatment Access and Recovery in Re-entry (STAR-R) | Univ of Massachusetts Med Sch Worcester | 2026 | $722,403 |
| Preventing Overdose and Promoting Recovery through Court Navigation | Research Triangle Institute | 2026 | $542,573 |
| Police Pathways to Addiction Treatment, Health, and Safety: The Police PATHS Study | Rhode Island Hospital | 2026 | $718,775 |
| Pathways to Treatment: Assessing Effectiveness and Implementation of Oregon's Deflection Programs for People who Use Drugs | Research Triangle Institute | 2026 | $633,328 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-25-062 still open?
No. It closed on January 22, 2025.
Who can apply for HEAL Initiative: JCOIN Phase II Innovation Hubs (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL Initiative: JCOIN Phase II Innovation Hubs (R01 Clinical Trial Optional)?
Closed January 22, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.3 million each.
Who has been funded under RFA-DA-25-062?
NIH RePORTER lists 9 projects funded under RFA-DA-25-062 in fiscal 2025 to 2026, at 7 institutions. The most were at Univ of Massachusetts Med Sch Worcester, Research Triangle Institute, University of Washington.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)